Skip to content

Richard Baird

  • MD, PhD
  • Academic Consultant in Experimental Cancer Therapeutics
  • University of Cambridge
  • 15h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 1790CitationsNumber of citations received by Richard's publications. Updated daily.

Recent publications

  • Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA

    • Gao M
    • Callari M
    • Beddowes E
    • et al.
    Get full text
  • A multi-centre, single arm, open label Phase Ib/IIa study to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients who have progressed on treatment with anastrozole or letrozole

    • Seckl M
    • Badman P
    • Liu X
    • et al.

Professional experience

Academic Consultant in Experimental Cancer Therapeutics

University of Cambridge

June 2011 - Present

Senior Clinical Research Fellow, Drug Development Unit

Royal Marsden Hospital & Institute of Cancer Research

September 2009 - June 2011(2 years)

Specialist Registrar in Medical Oncology

Royal Marsden Hospital

September 2005 - August 2009(4 years)

Clinical Research Fellow

Institute of Cancer Research

February 2002 - August 2005(4 years)

Training in general (internal) medicine

Hospitals in London and SE England

August 1997 - February 2002(5 years)


MRCP, General (Internal) Medicine

Royal College of Physicians

April 2001

MBBS, Medicine

King's College Medical School

September 1994 - June 1997(3 years)

MA, Social and Political Science

University of Cambridge

October 1991 - June 1994(3 years)


• Cancer researcher and medical oncologist at Cambridge University Hospitals, U.K. • Trained at University of Cambridge and Institute of Cancer Research / Royal Marsden Hospital. • Specialist in the care of breast cancer patients. • MD with PhD in molecular pharmacology and cancer drug development. • Expert in the testing of novel therapeutic approaches for breast cancer patients, including: o Design and delivery of early phase clinical trials as principal / chief investigator. o Looking after patients taking part in these trials. o Particular research focus on development of: novel targeted therapies; drug combinations; better approaches for patients with brain metastases; companion biomarkers to identify patients most likely to respond to treatment – including liquid biopsies / circulating tumor DNA o Collaboration with industry partners to plan the best clinical development strategy. • Since 2002 co- or Principal Investigator on >80 phase 1 / 2 clinical trials. • Currently Chief or co-Chief Investigator on 3 multi-centre investigator-initiated clinical trials. • Member of trial management group for national and international trials. • UK national academic lead for the Association of Cancer Physicians.

Co-authors (309)